読み込み中
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
前日終値
$15.36
+$0.32 · +2.13%
日中の時刻はETです。市場データは遅延する場合があります。
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
日中レンジ
現在 $15.36
52週レンジ
現在 $15.36
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
72
割安
センチメント
49
まちまち
リスク
37
中程度のリスク
モメンタム
65
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
日中レンジ
現在 $15.36
52週レンジ
現在 $15.36
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8523.1万 USD | 3720.5万 USD | 206.5万 USD | 271.9万 USD | 355.5万 USD |
| 売上原価 | 1179.7万 USD | 618.8万 USD | 63.5万 USD | 68.6万 USD | 67.1万 USD |
| 粗利益 | 7343.4万 USD | 3101.7万 USD | 143万 USD | 203.3万 USD | 288.4万 USD |
| 研究開発 | 2924.6万 USD | 1387.4万 USD | 1750.2万 USD | 1858.3万 USD | 1377.8万 USD |
| 販売・一般管理 | 4352.8万 USD | 2955.3万 USD | 2211万 USD | 1730.3万 USD | 1363.7万 USD |
| 営業費用 | 7277.4万 USD | 4342.7万 USD | 3961.2万 USD | 3588.6万 USD | 2741.5万 USD |
| 受取利息 | 292万 USD | 12.5万 USD | — | — | — |
| 支払利息 | — | — | 143.9万 USD | 268.5万 USD | 118.6万 USD |
| 減価償却費と償却費 | 34.9万 USD | 22.9万 USD | 12.8万 USD | 13.2万 USD | 14.6万 USD |
| 営業利益 | 66万 USD | −1241万 USD | −3818.2万 USD | −3385.3万 USD | −2453.1万 USD |
| 純利益 | 270万 USD | −2638.6万 USD | −4767.8万 USD | −3650.8万 USD | −2564.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$24.50
上昇余地（59.51%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1463.97万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1138.76万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF502.8万0.01%954億 USD0.05%$235+0.80%
Simplify Propel Opportunities ETFSURI346.46万4.56%7606.44万 USD2.82%$17.06-0.14%
Vanguard Russell 2000 ETFVTWO272.23万0.01%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS185.06万0.01%338.69億 USD0.31%$78.35+0.32%
State Street SPDR S&P Health Care Equipment ETFXHE151.15万0.87%1.74億 USD0.35%$89.47+1.51%
iShares Micro-Cap ETFIWC136.65万0.10%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASState Street SPDR S&P Health Care Equipment ETFXHEiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
